Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 612
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT02452996 Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers |
GNbAC1 | SEP | Phase 1 | COMPLETED | En attente / non publié | GeNeuro Australia PTY Ltd | Germany · PAREXEL Early Phase Clinical Unit, Berlin, … | 2015-04 → 2015-08 | Ouvrir |
| NCT01699555 First-in-Human Study With GNbAC1 in Healthy Volunteers |
GNbAC1 | SEP | Phase 1 | COMPLETED | En attente / non publié | GeNeuro Australia PTY Ltd | Non communiqué | 2011-07 → 2012-08 | Ouvrir |
| NCT06372145 A Study to Investigate Long-term Safety and Tolerability of Tolebrutini… |
Tolebrutinib | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Sanofi | United States, Argentina, Australia, Austria, Belgium… | 2024-04-16 → 2029-04-30 | Ouvrir |
| NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosin… |
Tolebrutinib | SEP | Phase 3 | COMPLETED | En attente / non publié | Sanofi | United States, Argentina, Australia, Austria, Belarus… | 2020-08-13 → 2025-11-14 | Ouvrir |
| NCT01142583 A Canadian Study Assessing the Utility of the Treatment Optimization Re… |
A Canadian Study Assessing the Ut… | SEP | À vérifier | COMPLETED | En attente / non publié | Merck KGaA, Darmstadt, Germany | Non communiqué | 2006-07 → 2009-08 | Ouvrir |
| NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerabi… |
Ponesimod | SEP | Phase 3 | COMPLETED | En attente / non publié | Actelion | United States, Belarus, Bosnia and Herzegovina, Bulga… | 2017-07-05 → 2024-01-16 | Ouvrir |
| NCT04833673 The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia… |
The Effects of Relaxation Techniq… | SEP | NA | COMPLETED | En attente / non publié | Hacettepe University | Turkey (Türkiye) · Hacettepe University, Ankara, Turk… | 2020-06-22 → 2021-03-15 | Ouvrir |
| NCT02117375 EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Rem… |
spinal cord MRI follow-up | SEP | NA | COMPLETED | En attente / non publié | Rennes University Hospital | France · CHU Rennes, Rennes, France | 2014-01 → 2024-01-24 | Ouvrir |
| NCT06196866 Effectiveness of Exergaming in Adittion to Conventional Treatment for P… |
Nintendo Ring Fit Adventure + Con… | SEP | NA | ACTIVE_NOT_RECRUITING | En attente / non publié | Universidad de Córdoba | Spain · University of Cordoba, Córdoba, Spain | 2023-09-01 → 2025-06-01 | Ouvrir |
| NCT03846219 MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Re… |
IMU-838 (30 mg/day) | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Immunic AG | Bulgaria, Poland, Romania, Ukraine · BioResearch Grou… | 2019-01-28 → 2029-12 | Ouvrir |
| NCT05049161 A Long-term Extension of Study GNC-401 |
Temelimab 18 mg/kg | SEP | Phase 2 | TERMINATED | En attente / non publié | GeNeuro Innovation SAS | Sweden · Center for Neurology, Academic Specialist Ce… | 2021-08-27 → 2022-05-18 | Ouvrir |
| NCT01639300 Safety Study of GNbAC1 in Multiple Sclerosis Patients |
GNbAC1 | SEP | Phase 2 | COMPLETED | En attente / non publié | GeNeuro Australia PTY Ltd | Switzerland · Hopitaux Universitaires de Genève - HUG… | 2012-07 → 2014-04 | Ouvrir |
| NCT04410991 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine … |
Tolebrutinib | SEP | Phase 3 | COMPLETED | En attente / non publié | Sanofi | United States, Argentina, Belgium, Brazil, Canada, Ch… | 2020-06-11 → 2024-07-16 | Ouvrir |
| NCT03996291 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Part… |
Tolebrutinib | SEP | Phase 2 | COMPLETED | En attente / non publié | Sanofi | United States, Canada, Czechia, Estonia, France, Neth… | 2019-09-23 → 2024-11-26 | Ouvrir |
| NCT04742400 Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for… |
tolebrutinib 60mg | SEP | Phase 2 | UNKNOWN | En attente / non publié | National Institute of Neurologica… | United States · National Institutes of Health Clinica… | 2021-04-15 → 2025-12-31 | Ouvrir |
| NCT06106074 Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR4421… |
Tolebrutinib | SEP | Phase 1 | COMPLETED | En attente / non publié | Sanofi | United States · New Orleans Clinical Research Site Nu… | 2020-08-10 → 2022-05-23 | Ouvrir |
| NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of… |
Tolebrutinib | SEP | Phase 3 | COMPLETED | En attente / non publié | Sanofi | United States, Argentina, Australia, Austria, Belarus… | 2020-09-24 → 2024-08-29 | Ouvrir |
| NCT06292923 A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple… |
Foralumab | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Tiziana Life Sciences LTD | United States · Brigham and Women's Hospital, Boston,… | 2023-11-15 → 2026-10 | Ouvrir |
| NCT05029609 Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Seco… |
Intranasal Foralumab Solution | SEP | Phase 1 | WITHDRAWN | En attente / non publié | Tiziana Life Sciences LTD | Non communiqué | 2021-10 → 2022-12 | Ouvrir |
| NCT06802328 Intermediate-Size Patient Population Expanded Access: Foralumab in Non-… |
Foralumab TZLS-401 50 µg | SEP | À vérifier | AVAILABLE | En attente / non publié | Tiziana Life Sciences LTD | United States · Brigham and Women's Hospital, Boston,… | Non communiqué | Ouvrir |
| NCT04414345 HEALEY ALS Platform Trial - Regimen C CNM-Au8 |
CNM-Au8 | SEP | Phase 2 | COMPLETED | En attente / non publié | Clene Nanomedicine | United States · Healey Center for ALS at Mass General… | 2020-07-30 → 2023-03-07 | Ouvrir |
| NCT04081714 Intermediate Expanded Access Protocol CNMAu8.EAP03 |
CNM-Au8 | SEP | À vérifier | TEMPORARILY_NOT_AVAILABLE | En attente / non publié | Clene Nanomedicine | United States · University of Texas Southwestern, Dal… | Non communiqué | Ouvrir |
| NCT04098406 Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic La… |
CNM-Au8 | SEP | Phase 2 | COMPLETED | En attente / non publié | Clene Nanomedicine | Australia · University of Sydney Brain and Mind Centr… | 2019-12-19 → 2021-07-13 | Ouvrir |
| NCT04725175 Phase I Study Evaluating Safety and Tolerability of Escalating Single a… |
PIPE-307 | SEP | Phase 1 | COMPLETED | En attente / non publié | Contineum Therapeutics | Australia · Linear Clinical Research, Nedlands, Austr… | 2021-02-26 → 2021-09-01 | Ouvrir |
| NCT04941781 PET Study to Determine the Relationship Between Plasma Concentrations a… |
PIPE-307 | SEP | Phase 1 | COMPLETED | En attente / non publié | Contineum Therapeutics | United Kingdom · Hammersmith Medicines Research, Lond… | 2021-09-01 → 2021-11-10 | Ouvrir |